Bladder cancer, version 3.2020
Bladder cancer, version 3.2020
复制标题
膀胱癌，版本 3.2020
DOI：
10.6004/jnccn.2020.0010
复制
发表时间：
2020
影响因子：
13.4
通讯作者：
Alyse Johnson
中科院分区：
文献类型：
--
作者：
T. Flaig;P. Spiess;N. Agarwal;R. Bangs;S. Boorjian;M. Buyyounouski;Sam S. Chang;T. Downs;J. Efstathiou;T. Friedlander;R. Greenberg;K. Guru;T. Guzzo;H. Herr;J. Hoffman;C. Hoimes;B. Inman;M. Jimbo;A. Kader;S. Lele;J. Michalski;J. Montgomery;L. Nandagopal;L. Pagliaro;S. Pal;A. Patterson;E. Plimack;K. Pohar;M. Preston;W. Sexton;A. Siefker;J. Tward;J. Wright;Lisa A. Gurski;Alyse Johnson
从《NCCN膀胱癌临床实践指南》(NCCN指南)中选择的内容主要集中在疑似膀胱癌的临床表现和体检、非肌肉浸润性尿路上皮癌的治疗以及转移性尿路上皮癌的治疗，因为最近对这些部分进行了重要更新。一些重要的更新包括在卡介苗(BCG)短缺的情况下非肌肉浸润性膀胱癌的最佳治疗建议和细节
This selection from the NCCN Clinical Practice Guidelines in On- cology (NCCN Guidelines) for Bladder Cancer focuses on the clinical presentation and workup of suspected bladder cancer, treatment of non – muscle-invasive urothelial bladder cancer, and treatment of metastatic urothelial bladder cancer because important updates have recently been made to these sections. Some important updates include recommendations for optimal treatment of non – muscle-invasive bladder cancer in the event of a bacillus Calmette-Gu´erin (BCG) shortage and details